Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor-Case Report.

Authors

Zachray Wei, Tamara Marconi, Lucy Tuck, Stephen Ting

Published in

EJHaem. Volume 7. Issue 5. Pages e70423. Epub Oct 09, 2026.

Abstract

Although Immune cytopenias such as immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AIHA) and pure red blood cell aplasia (PRCA) are well documented associations with chronic lymphocytic leukaemia (CLL), aplastic anaemia (AA) is seemingly rare.
This report describes a case of AA in a CLL patient post commencement of acalabrutinib, a bruton tyrosine kinase inhibitor (BTKi).
We further evaluate the current literature surrounding AA in concurrent lymphoproliferative disorders as well as previous cases in the setting of tyrosine kinase inhibition. Highlighting the potential pathophysiological pathways of T regulatory cell dysfunction resulting in immune targeting of haematopoietic stem progenitor cells, we explore the resultant AA as an aberrant immune response secondary to CLL and/or the inhibition of BTKi.
The authors have confirmed clinical trial registration is not needed for this submission.

PMID:
42859467
Bibliographic data and abstract were imported from PubMed on 11 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.